Lantern Pharma Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LTRN | CLRB | PCSA | TPST | APLM | CRIS | |
|---|---|---|---|---|---|---|
| Market cap | 11.01M | 13.52M | 5.31M | 12.54M | 62.15M | 1.56M |
| P/E (TTM) | — | — | — | — | — | 0.5 |
| Forward P/E | -0.4 | -0.7 | -0.5 | -0.6 | -32.8 | -0.1 |
| Price/book | -2.9 | 0.4 | -16.7 | 13.0 | -14.4 | 0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −81.56% | −70.35% | −86.21% | −93.41% | +15.66% | −97.69% |
| Today | −9.31% | −1.38% | +25.00% | −2.29% | −0.84% | −4.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LTRN news ›Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
Lantern Pharma has secured regulatory and Institutional Review Board (IRB) clearances in Taiwan to initiate Part 2 of its Phase II HARMONIC clinical trial of LP-300 in combination with carboplatin and pemetrexed in never-smokers with…
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
In the United States, a central IRB has approved the amended protocol, and academic clinical sites have begun identifying patients whose tumors carry the EGFR exon 21 L858R mutation. Patients enrolled under the amended protocol will be…
Lantern Pharma Closes $4 Million Registered Direct Offering to Advance AI-Driven Oncology Pipeline
citybuzz - Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company that uses artificial intelligence and genomic data to develop precision oncology therapies, announced the closing of a previously announced registered…
Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering
The Globe and Mail Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision…
Lantern Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard
TradingView Lantern Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard On September 25, 2026, the company received notice from Nasdaq that it failed to meet Listing Rule 5550(b)(2) as its market value of listed…
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
BioSpace Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering $4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants…
Lantern Pharma Raises $4.0 Million in Registered Direct; Issues Warrants, Engages Rodman & Renshaw
TradingView Lantern Pharma Raises $4.0 Million in Registered Direct; Issues Warrants, Engages Rodman & Renshaw Lantern Pharma raised approximately $4.0 million via a registered direct offering and a concurrent private placement of warrants…
Lantern Pharma announces up to $8M registered direct offering (LTRN:NASDAQ)
Lantern Pharma (LTRN) announces a $4M registered direct offering and private placement warrants priced at $1.09, expected to close Sept.
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
tradingview.com3
-
biospace.com2
-
citybuzz.co1
-
seekingalpha.com1
-
theglobeandmail.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.